NEW YORK (TheStreet) --  MSCI's move to exclude China's A-listed shares from its well-known Emerging Markets Index is making one strategist cautious.

"We're a little concerned about the parabolic move we've seen in the A-Share market," said Mark Luschini, chief investment strategist at Janney Montgomery Scott. "But the H-Shares, which are Chinese-domiciled companies traded and listed in Hong Kong, are selling at a 25% discount to their A-Share counterparts, so there's much better valuation there."

He said Chinese stocks have been bid up due to anticipation that they would be included in the index, and also based on stimulus from the People's Bank of China, which is why he suggests being 'long, but cautious.'

Luschini said MSCI's decision was largely due to the immaturity of the Chinese market. "It's notorious that stocks listed in China are subject to a lot of retail buying and selling -- a lot of speculation, if not outright manipulation," he said.

The iShares MSCI Emerging Markets ETF has returned about 2% since the start of the year.

Stocks in China didn't react well to the news. The Shanghai Composite closed Wednesday's trading day at 5106.04, down 0.15%, after reaching an intraday high of 5162.79.

He said investors who have not yet made a commitment to investing in China should wait until the Chinese central bank's stimulus efforts have done more to improve economic conditions.

"We need to see the stimulus measures from the People's Bank of China actually start to work in the economy and right now there isn't clear evidence that's occurring," he said.

Meanwhile, Luschini's summer strategy centers around the financials sector. "With the slight uptick we've had in interest rates recently, there's opportunity for the banks' net interest margin to expand."

Yields on the benchmark 10-year Treasury stand at 2.46%, compared to 2.12% at the beginning of the year.

Financial stocks in the S&P 500 have fallen 0.4% since the start of the year, and include names like Bank of America (BAC), JPMorgan Chase (JPM) and Wells Fargo (WFC).

Luschini is also bullish on Gilead Sciences (GILD).

"It's trading at 10 times earnings, so you have good valuations, compared to the market and the health care sector," he said.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

More from Investing

How to Trade CyrusOne Stock Right Now

How to Trade CyrusOne Stock Right Now

Here's Why General Electric CEO Larry Culp Is a Proven Asset

Here's Why General Electric CEO Larry Culp Is a Proven Asset

AMD Slides After Target Price Is Cut at Baird

AMD Slides After Target Price Is Cut at Baird

It's Another Disappointing Day of Action...So Far

It's Another Disappointing Day of Action...So Far

Cannabis Roundup: DAVIDsTEA Preps Earnings, Aurora Cannabis Tumbles

Cannabis Roundup: DAVIDsTEA Preps Earnings, Aurora Cannabis Tumbles